UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549  
 
FORM 8-K  
 
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): August 8, 2017
 
American Renal Associates Holdings, Inc.
(Exact name of registrant as specified in its charter)
 
Delaware
 
001-37751
 
27-2170749
(State or other jurisdiction
of Incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification Number)

500 Cummings Center, Suite 6550
Beverly, Massachusetts
 
01915
(Address of registrant’s principal executive office)
 
(Zip code)

(978) 922-3080
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:  
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 203.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
☒
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☒
 






 

 
 
Item 2.02
Results of Operations and Financial Condition.
 
On August 8, 2017 , American Renal Associates Holdings, Inc. issued a press release announcing its financial and operating results for the second quarter ended June 30, 2017 .  A copy of the press release is furnished with this report as Exhibit 99.1 and is incorporated by reference into this item.
 
As provided in General Instruction B.2 of Form 8-K, the information and exhibit contained in this report shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing. 

 
 
Item 9.01.
Financial Statements and Exhibits.
(d) Exhibits.
 
Exhibit
Number
 
Description
99.1
 
Press release, dated August 8, 2017, announcing the registrant’s financial and operating results for the second quarter ended June 30, 2017.






 

SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
 
AMERICAN RENAL ASSOCIATES HOLDINGS, INC.
 
 
 
 
Dated: August 8, 2017
 
 
 
By:
 
/s/ Jonathan L. Wilcox
 
 
 
 
Name:
 
Jonathan L. Wilcox
 
 
 
 
Title:
 
Chief Financial Officer




 
EXHIBIT INDEX
 
 
 
Exhibit
Number
 
Description
99.1
 
Press release, dated August 8, 2017, announcing the registrant’s financial and operating results for the second quarter ended June 30, 2017.


American Renal Associates (NYSE:ARA)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024 Click aqui para mais gráficos American Renal Associates.
American Renal Associates (NYSE:ARA)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024 Click aqui para mais gráficos American Renal Associates.